Antje M. Wengner

2.7k citations

45 papers · 1.7k indexed · h-index 19

Molecular Biology top 10%
Oncology top 5%
Immunology top 10%
Organic Chemistry top 10%
Genetics top 5%

Co-authors: Simon C. Pitchford Rebecca C. Furze Sara M. Rankin Dominik Mumberg Philip Lienau Gerhard Siemeister Karl Ziegelbauer Carla P. Jones
Topics: DNA Repair Mechanisms (12 papers)Cancer-related Molecular Pathways (12 papers)PARP inhibition in cancer therapy (8 papers)
Cited by: Oncology Genetics Immunology
Journals: Journal of Clinical Oncology Blood Cancer Cell
Partner nations: Germany United States United Kingdom

In The Last Decade

Antje M. Wengner

44 papers receiving 1.7k citations

Peers

Countries citing papers authored by Antje M. Wengner

Since Specialization

Citations

This map shows the geographic impact of Antje M. Wengner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antje M. Wengner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antje M. Wengner more than expected).

Fields of papers citing papers by Antje M. Wengner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antje M. Wengner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antje M. Wengner. The network helps show where Antje M. Wengner may publish in the future.

Co-authorship network of co-authors of Antje M. Wengner

This figure shows the co-authorship network connecting the top 25 collaborators of Antje M. Wengner. A scholar is included among the top collaborators of Antje M. Wengner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antje M. Wengner. Antje M. Wengner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations 2025 ·Molecular Cancer Therapeutics ·(unknown),(unknown),Kurt W. Evans,Maria Gabriela Raso,(unknown),(unknown),Dhruv Chachad,Timothy P. DiPeri,(unknown),(unknown),Ming Zhao,Argun Akçakanat,Antje M. Wengner,Timothy A. Yap,Funda Meric‐Bernstam	1
2	The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib 2023 ·British Journal of Haematology ·Giulio Sartori,Chiara Tarantelli,Filippo Spriano,Eugenio Gaudio,Luciano Cascione,(unknown),Marilia Barreca,Alberto J. Arribas,(unknown),Gaetanina Golino,(unknown),Stefano Pileri,Giovanna Damia,Emanuele Zucca,Anastasios Stathis,Oliver Politz,Antje M. Wengner,Francesco Bertoni	7
3	Targeted thorium-227 conjugates as treatment options in oncology 2023 ·Frontiers in Medicine ·Jenny Karlsson,Christoph A. Schatz,Antje M. Wengner,Stefanie Hammer,Arne Scholz,Alan Cuthbertson,Volker Jean Wagner,Hartwig Hennekes,(unknown),Urs B. Hagemann	17
4	Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations 2021 ·Molecular Cancer Therapeutics ·(unknown),Dali Li,(unknown),Kurt W. Evans,Maria Gabriela Raso,Timothy P. DiPeri,(unknown),Min Jin Ha,Huiqin Chen,Ming Zhao,Argun Akçakanat,Xiaofeng Zheng,Gökçe Törüner,Erkan Yuca,Stephen Scott,Antje M. Wengner,Timothy A. Yap,Funda Meric‐Bernstam	0
5	The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models 2019 ·Molecular Cancer Therapeutics ·Antje M. Wengner,Gerhard Siemeister,Ulrich Lücking,Julien Lefranc,Lars Wortmann,Philip Lienau,Benjamin Bader,Ulf Bömer,Dieter Moosmayer,Uwe Eberspächer,Sven Golfier,Christoph A. Schatz,Simon J. Baumgart,Bernard Haendler,Pascale Lejeune,Andreas Schlicker,Franz von Nussbaum,Michael Brands,Karl Ziegelbauer,Dominik Mumberg	145
6	Synergistic Effect of a Mesothelin-Targeted ²²⁷Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models 2019 ·Journal of Nuclear Medicine ·(unknown),Urs B. Hagemann,Véronique Cruciani,Antje M. Wengner,Alexander Kristian,Christine Ellingsen,Gerhard Siemeister,Roger M. Bjerke,Jenny Karlsson,Olav B. Ryan,Lars Lindén,Dominik Mumberg,Karl Ziegelbauer,Alan Cuthbertson	40
7	Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344 2019 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown),Urs B. Hagemann,Alexander Kristian,Christine Ellingsen,Anette Sommer,Heidrun Ellinger‐Ziegelbauer,(unknown),(unknown),(unknown),(unknown),Roger M. Bjerke,Jenny Karlsson,Olav B. Ryan,Antje M. Wengner,Lars Lindén,Dominik Mumberg,Alan Cuthbertson	18
8	Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing 2019 ·ACS Medicinal Chemistry Letters ·Timothy A. Lewis,Luc de Waal,Xiaoyun Wu,Willmen Youngsaye,Antje M. Wengner,Charlotte Kopitz,Martin Lange,Stefan Gradl,Manuel Ellermann,Philip Lienau,Stuart L. Schreiber,Heidi Greulich,Matthew Meyerson	20
9	Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT 2017 ·Cancer Cell ·(unknown),(unknown),Antje M. Wengner,Sabine Zitzmann-Kolbe,(unknown),(unknown),(unknown),Sze Huey Tan,Martin Lange,Soo‐Yong Tan,Dominik Mumberg,Soon Thye Lim,Karl Ziegelbauer,Ningshu Liu	101
10	BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity 2017 ·Cancer Letters ·(unknown),Franziska Siegel,Antje M. Wengner,Claudia Lange,Ulf Bömer,Knut Eis,(unknown),Philip Lienau,(unknown),Martin Michels,Franz von Nussbaum,Dominik Mumberg,Kirstin Petersen	48
11	Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models 2017 ·Cancer Research ·(unknown),Julien Lefranc,Antje M. Wengner,Lars Wortmann,Hans Schick,Hans Briem,Gerhard Siemeister,Philip Lienau,Christoph A. Schatz,Benjamin Bader,(unknown),Franz von Nussbaum,Michael Brands,Dominik Mumberg,Karl Ziegelbauer	12
12	Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity 2016 ·Molecular Cancer Therapeutics ·Antje M. Wengner,Gerhard Siemeister,Marcus Koppitz,Volker Schulze,Dirk Kosemund,Ulrich Klar,Detlef Stoeckigt,Roland Neuhaus,Philip Lienau,Benjamin Bader,Stefan Prechtl,Marian Raschke,Anna-Lena Frisk,Oliver von Ahsen,Martin Michels,Bertolt Kreft,Franz von Nussbaum,Michael Brands,Dominik Mumberg,Karl Ziegelbauer	85
13	Characterization of novel MPS1 inhibitors with preclinical anticancer activity 2013 ·Cell Death and Differentiation ·Mohamed Jèmaà,Lorenzo Galluzzi,Oliver Kepp,Laura Senovilla,Michael Brands,Ulf Boemer,Marcus Koppitz,Philip Lienau,Stefan Prechtl,Volker Schulze,Gerhard Siemeister,Antje M. Wengner,Dominik Mumberg,Karl Ziegelbauer,Ariane Abrieu,Maria Castedo,Ilio Vitale,Guido Kroemer	83
14	The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer 2013 ·ChemMedChem ·Ulrich Lücking,Rolf Jautelat,Martin Krüger,Thomas Brumby,Philip Lienau,Martina Schäfer,Hans Briem,(unknown),Alexander Hillisch,Andreas Reichel,Antje M. Wengner,Gerhard Siemeister	152
15	BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application 2012 ·Molecular Cancer Therapeutics ·Gerhard Siemeister,Ulrich Lücking,Antje M. Wengner,Philip Lienau,Wolfram Steinke,Christoph A. Schatz,Dominik Mumberg,Karl Ziegelbauer	131
16	Abstract 4503: BAY 87-2243, an inhibitor of HIF-1α activation and stabilization, showed promising anti-tumor efficacy either as monotherapy or in combination with anti-VEGF and chemotherapy agents in preclinical tumor models 2011 ·Cancer Research ·(unknown),Peter Ellinghaus,Michael Haerter,Susanne Greschat,Antje M. Wengner,Arne Scholz,Andrea Haegebarth,Holger Hess‐Stumpp	3
17	Differential Mobilization of Subsets of Progenitor Cells from the Bone Marrow 2009 ·Cell stem cell ·Simon C. Pitchford,Rebecca C. Furze,Carla P. Jones,Antje M. Wengner,Sara M. Rankin	219
18	The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation 2007 ·Blood ·Antje M. Wengner,Simon C. Pitchford,Rebecca C. Furze,Sara M. Rankin	177
19	CXCR5‐ and CCR7‐dependent lymphoid neogenesis in a murine model of chronic antigen‐induced arthritis 2007 ·Arthritis & Rheumatism ·Antje M. Wengner,Uta E. Höpken,Peter Petrow,(unknown),Uta Schurigt,Rolf Bräuer,Martin Lipp	90
20	CCR7 deficiency causes ectopic lymphoid neogenesis and disturbed mucosal tissue integrity 2006 ·Blood ·Uta E. Höpken,Antje M. Wengner,Christoph Loddenkemper,Harald Stein,Markus M. Heimesaat,Armin Rehm,Martin Lipp	52

About Antje M. Wengner

Antje M. Wengner is a scholar working on Oncology, Genetics and Immunology, having authored 45 papers that have together received 1.7k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (12 papers), Cancer-related Molecular Pathways (12 papers) and PARP inhibition in cancer therapy (8 papers). The work is most often cited by research in Oncology (597 citations), Genetics (213 citations) and Immunology (349 citations). Antje M. Wengner has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Simon C. Pitchford, Rebecca C. Furze, Sara M. Rankin, Dominik Mumberg, Philip Lienau, Gerhard Siemeister, Karl Ziegelbauer, Carla P. Jones, Ulrich Lücking and Martin Lipp. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact